Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 3/20 | 0.50 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | BCL2 | P10415 | 2/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.30 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.30 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1562420 | 0.96 | S1PR1 (0.53) | S1PR1S1PR3CYP2C9PTGER1BCL2 | |
| SCHEMBL13259280 | 0.94 | S1PR1 (0.48) | S1PR1S1PR3CYP2C9PTGER1MTNR1B | |
| SCHEMBL2968772 | 0.91 | S1PR1 (0.51) | S1PR1S1PR3CYP2C9PTGER1MTNR1B | |
| SCHEMBL1563102 | 0.90 | S1PR1 (0.49) | S1PR1S1PR3CYP2C9PTGER1MTNR1B | |
| SCHEMBL13259292 | 0.90 | S1PR1 (0.51) | S1PR1S1PR3CYP2C9PTGER1BCL2 | |
| SCHEMBL1563269 | 0.90 | S1PR1 (0.51) | S1PR1S1PR3CYP2C9PTGER1MTNR1B | |
| SCHEMBL1562444 | 0.89 | S1PR1 (0.55) | S1PR1S1PR3CYP2C9PTGER1MTNR1B | |
| SCHEMBL1564193 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3CYP2C9PTGER1BCL2 | |
| SCHEMBL1563185 | 0.87 | S1PR1 (0.54) | S1PR1S1PR3CYP2C9PTGER1FFAR1 | |
| SCHEMBL1562410 | 0.86 | S1PR1 (0.52) | S1PR1S1PR3CYP2C9PTGER1BCL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172472-B1 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | KYORIN SEIYAKU KK (JP) | 2012-12-26 | — | — | EP | disclosed |
| EP-1602660-B1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | KYORIN SEIYAKU KK (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-7759326-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2172472-A2 | Aminophosphonic acid derivative, salt thereof and modulator of S1P receptor | Kyorin Pharmaceutical Co., Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7456157-B2 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2008-11-25 | — | — | US | disclosed |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KOHNO YASUSHI | 2008-11-06 | — | — | US | disclosed |
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2006-07-20 | — | — | US | disclosed |
| EP-1602660-A1 | AMINOPHOSPHONIC ACID DERIVATIVES, ADDITION SALTS THEREOF AND S1P RECEPTOR MODULATORS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2005-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160771-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885CYP2C9 1800/4885 |
| US-20080275008-A1 | Modulate sphingosine-1-phosphate (S1P) receptors with fewer side effects; for example, 2-amino-5-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]-2-methylpentylphosphonic acid monoester; prophylactic or therapeutic agents against rejection of organ transplants, skin grafts, rheumatoid arthritis, lupus | S1PR1, S1PR2, S1PR5 | S1PR1 1/4885S1PR3 4/4885CYP2C9 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.